Sanofi spies more potential for IL-10 in Synthekine's research

1 February 2024
research_biotech_lab_big

Californian firm Synthekine, a specialist in engineered cytokine therapeutics, has agreed a global collaboration with Sanofi (Euronext: SAN).

The deal will see the companies working together to develop and commercialize interleukin (IL)-10 receptor agonists for the treatment of inflammatory diseases.

In particular, research will focus on advancing Synthekine’s multiple techniques for optimizing IL-10, with the goal of enhancing the therapeutic benefits of this approach.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology